Search
Gavorestat
go.drugbank.com/drugs/DB16707InvestigationalGavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).
Synonyms: 2-(4-Oxo-3-((5-(Trifluoromethyl)Benzo[D]Thiazol-2-Yl)Methyl)-3,4-Dihydrothieno[3,4-D]Pyridazin-1-Yl)Acetic AcidClomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Categories: P-glycoprotein substratesSynonyms: 2-(p-(β-chloro-α-phenylstyryl)phenoxy)triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylaminePravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalPravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug....
Categories: P-glycoprotein substratesProducts: Nu-pravastatin TabletsIONIS-FGFR4Rx
go.drugbank.com/drugs/DB16198InvestigationalIONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigationalWomen undergoing abrupt menopause due to oophorectomy also experienced more severe symptoms than those going through a gradual transition. … [A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesPI-166
go.drugbank.com/drugs/DB05859ExperimentalPI-166 is a small organic compound with specific avidity to liver cancer cells.
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[Olanzapine] is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes. … antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability, and a longer half-life, making it an
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesParaldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.
Fluorodopa (18F)
go.drugbank.com/drugs/DB13848ApprovedInvestigationalFluorodopa F 18 is a fluorinated analog of levodopa used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes. Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations...
PX-12
go.drugbank.com/drugs/DB05448InvestigationalInitial trials correlated doses of Px-12 with increased patient survival. … PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits